Journey of Aurobindo Pharma Limited (APL)

Founded in 1986, Aurobindo Pharma Limited (APL) is a pharmaceutical company that is involved in the development, manufacture and sale of Active Pharma Ingredients (API) and formulations. The company started their operations in 1988-1989 with a single manufacturing unit at Pondicherry to manufacture Semi Synthetic Penicillins (SSPs).  Between 1992-1993, they set up another manufacturing facility in Hyderabad to manufacture CMIC Chloride, a bulk drug intermediate. In 1994, the company merged with Chaitanya Organics Pvt. Ltd and started the commercial production of the pharmaceutical formulation unit. In 1995, Aurobindo Pharma Limited went public. Since then, the company has expanded its product base and started manufacturing various formulations. From  2003 to 2004, the company set up a subsidiary in China and started commercial production. Between 2005 to 2006, Aurobindo Pharma Limited gained complete control of UK-based Milpharm Limited, which is involved in marketing generic formulations in the UK market. They established their presence worldwide in Brazil, the USA, Puerto Rico and Portugal. As of March 2023, Aurobindo Pharma Limited has 25 State-of-the-art manufacturing and packaging facilities, with export presence in more than 150 countries, 9 R&D centres and over 1,500 scientists and analysts involved in R&D activities.

Business Segments of Aurobindo Pharma Limited

• API:Under this segment, Aurobindo Pharma Limited develops and manufactures APIs. Their five manufacturing units are inspected and approved by the US FDA, ANVISA, TGA Australia, UK MHRA and other trusted regulatory agencies.

• Antiretroviral (ARV):Under this, the organization works with an aim to offer a wide range of high-quality antiretroviral drugs (US FDA Approved) for PLHIV & CLHIV.

• AuroZymes:This is the biocatalysts division of APL that develops and produces biocatalysts that can be utilised in the Chemical and Pharmaceutical Industries.

• Custom Synthesis:In this segment, the company offers customer-centric project-based chemistry services through their custom research and manufacturing division, AuroSource.

• Formulations:Under this segment, APL is involved in cost-effective drug development and substantial manufacturing.

• Peptides:In this segment, the organization develops peptide-based generic APIs, specifically core prioritying on diabetology and oncology segments.

• R&D:The R&D segment of the organization is involved in developing new drug delivery systems and new dosage formulations.

As of March 31, 2023, some of the subsidiaries of Aurobindo Pharma Limited are as follows:

• Helix Healthcare B.V.:This subsidiary of the organization is involved in the healthcare sector.
• Aurovitas Pharma Polska:This is a wholly-owned subsidiary of the organization that core priorityes on generic, Rx and OTC drugs covering 22 therapeutic areas.
• Milpharm Limited:This wholly-owned subsidiary of the organization that manufactures pharma products.

Key Personalities of Aurobindo Pharma Limited

Nityananda Reddy, Managing Director and Chairman Nityananda Reddy is the Chairman and Managing Director of Aurobindo Pharma Limited. He has been associated with APL since its initial days. He has experience in manufacturing technology and oversees the overall affairs of the company.

Corporate Actions of Aurobindo Pharma Limited

The company issued a bonus share of a 1:1 ratio with a record date of July 21, 2015.